Literature DB >> 32990951

Epilepsy and lockdown: A survey of patients normally attending a Spanish centre.

Estefanía Conde Blanco1, Isabel Manzanares1, María Centeno1, Mariam Khawaja1, Olga Betrán1, Antonio Donaire1, Mar Carreño1.   

Abstract

BACKGROUND: Lockdown due to the SARS-CoV-2 pandemic became a challenge to maintain care for patients with epilepsy; we aimed to find out how the pandemic affected them.
METHODS: We sent an online 22-item questionnaire to patients from our outpatient clinic, a reference centre in Spain for drug-resistant epilepsy, inquiring about the effects of lockdown, from March to May 2020.
RESULTS: We sent the survey to 627 patients; 312 (58% women) sent a complete response and were included. Of all respondents, 57% took >2 antiseizure medications. One-third of respondents (29%) declared an associated cognitive or motor disability. A minority had confirmed infection with SARS-CoV-2 (1.92%). Seizure frequency remained like usual in 56% of patients, while 31.2% reported an increase. Less than 10% needed emergent assistance. Almost half reported anxiety or depression, and 25% increased behavioural disorders. Mood (F: 5.40; p: 0.002) and sleep disorders (F = 2.67; p: 0.05) were associated with increase in seizure frequency. Patients were able to contact their physicians when needed and were open to a future telematic approach to follow-up visits.
CONCLUSIONS: Seizure frequency and severity remained unchanged in most patients during the lockdown. Mood and sleep disorders were common and associated with seizure worsening. Patients were open to telematic care in the future.
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  COVID-19; epilepsy; neuroepidemiology

Mesh:

Substances:

Year:  2020        PMID: 32990951      PMCID: PMC7646661          DOI: 10.1111/ane.13354

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.915


BACKGROUND

Lockdown due to SARS‐CoV‐2, which lasted ten weeks in Spain, from 15 March to 25 May 2020, proved to be a physical and psychological challenge for the general population . Patients with chronic disorders have experienced special difficulties, even when their disease per se does not put them at significant risk for infection . We aimed to find out the effect of the lockdown on our patients with chronic (often drug resistant) epilepsy (PWE), and the possible changes in seizure frequency and severity, mood and sleep quality during that time. We also inquired about telematic visits during these months.

PATIENTS AND METHODS

We performed an informal online survey addressed to the patients attended in our outpatient epilepsy clinic, a national reference centre for drug‐resistant epilepsy and epilepsy surgery, during the previous year. Only patients who had agreed to provide their e‐mail for communication could be contacted. The survey was approved by our hospital ethics committee and sent through an IT hospital platform, using Lyme survey. The questionnaire is available as online content (Appendix S2).

RESULTS

The survey was sent to 627 patients and 341 responded. In the analysis, we included 312 (181 women, 58.6%) complete responses. The majority (51.6%) of patients were 30–50 years old. See Appendix S1 for demographic and clinical details. Most patients had long‐standing epilepsy, with time since diagnosis >20 years in 45.2% of patients. Almost a third of patients (28.2%) were on 2 antiseizure medications (ASM), and 26% on only one; the rest were having ≥3. Of all respondents, 38.7% had been seizure free for years and 25% for some months. Sixteen per cent of respondents were having monthly seizures despite their medications, and 29% declared to have some associated cognitive or motor disability. During the lockdown, most patients (56.7%) did not work, 20.2% worked from home and only 13.14% continued to go to their workplace. Regarding coronavirus infection, 85.5% were not infected during the pandemic. Only 1.92% had reverse transcription polymerase chain reaction (RT‐PCR)‐confirmed infection, and another 9.29% had suggestive symptoms but were not tested. During the lockdown, 131 patients reported some seizures. Of the 128 who responded to the question of seizure frequency, 72 (56.25%) considered their seizure frequency to be similar to the one before lockdown, while 33 (25.8%) had more frequent seizures, 7 (5.4%) much more frequent seizures and 16 (12.5%) less frequent seizures. Similarly, 91/126 patients (72%) considered that seizure severity and duration were similar to the ones before lockdown. Only 17 (13.4%) considered that their seizures were longer or more severe. Seizures did not happen with fever, fatigue or other symptoms suggestive of coronavirus infection in the majority of patients (124, 94.6%). Some type of rescue treatment (oral, rectal or buccal benzodiazepines) to stop seizures was required in 34 patients. Only 11 patients required emergent assistance for seizures and were transferred to the emergency room. The patients were also asked about mood (anxiety, depression) and behaviour disorders (irritability and bad mood, see questionnaire, Appendix S2) during lockdown. Almost half (47%) reported having felt more anxious or depressed than usual and another 25% reported increased irritability or bad mood. However, almost 90% denied having contacted with psychology or psychiatry to obtain professional help. An increase in seizure frequency was reported by 45% and 51% of patients having mood or behaviour disorders, respectively. We found significant differences in seizure frequency among patients with increased mood disorders (F = 5.40; p: 0.002) but not with increased behaviour disorders (F: 3.60; p: 0.06). Regarding sleep, 43.27% of respondents admitted having difficulties with sleep during the lockdown, due mainly to difficulty to fall sleep (reported by 60%) and frequent awakenings (reported by 62.22%). Only 22.9% declared that their main problem was early awakening. Sleep problems were also associated to increased seizure frequency (F = 2.67; p: 0.05). Figure 1.
FIGURE 1

Seizure frequency change during the COVID‐19 pandemic according to sleep disturbances, behaviour or mood problems and cognitive impairment. We show a bar chart to capture the reported categories of seizure frequency in our patients with sleep, mood, behaviour and cognitive disability. An increase in seizure frequency was reported by 45% of patients who had been experiencing mood disorders and 51% of those with behaviour disorders. Regarding sleep, 43% of respondents admitted having difficulties with sleep during the lockdown. A third of the patients with cognitive disabilities associated with their epilepsy experienced an increase in seizure frequency. Abbreviation: Sz: seizure

Seizure frequency change during the COVID‐19 pandemic according to sleep disturbances, behaviour or mood problems and cognitive impairment. We show a bar chart to capture the reported categories of seizure frequency in our patients with sleep, mood, behaviour and cognitive disability. An increase in seizure frequency was reported by 45% of patients who had been experiencing mood disorders and 51% of those with behaviour disorders. Regarding sleep, 43% of respondents admitted having difficulties with sleep during the lockdown. A third of the patients with cognitive disabilities associated with their epilepsy experienced an increase in seizure frequency. Abbreviation: Sz: seizure Telephone follow‐up visits during lockdown were performed in 76/312 patients. When asked about the possibility of having this type of visits in the future, 11 (14%) answered yes (all visits if possible), 42 (55.2%) were open to have at least some of the follow‐up visits in this format, and 23 (30%) stated that they preferred onsite visits. We evaluated if demographic or epilepsy factors influenced the patients’ preference for telematic visits, but we found no significant association (Table 1).
TABLE 1

Results of the survey

Characteristics of the patients who completed the surveyTotal (n: 312)
(n; %)
Sex (Females)181 (58.0)
Age group (years)
10–181 (0.3)
18–3069 (22.1)
30–50161 (51.6)
50–7072 (23.1)
>709 (2.9)
Cognitive impairment91 (29.2)
Antiseizure medication
182 (26.3)
288 (28.2)
361 (19.6)
>381 (26.0)
Seizure intensity during lockdown
Less intense18 (14.3)
Similar to previous lockdown91 (72.2)
More intense17 (13.5)
Seizures required hospital care11 (8.4)
Epilepsy duration
1–535 (11.2)
5–1047 (15.1)
10–2089 (28.5)
>20141 (45.2)
SARS‐CoV−2 infection
Negative testing267 (85.6)
Positive testing6 (1.9)
No symptoms but contact with COVID−19+ person10 (3.2)
Presented consistent symptoms but not tested29 (9.3)
Results of the survey Most patients (243/312) needed to contact at some point with the neurologist or the epilepsy nurse. The great majority, 170 (70%) reported having had no difficulty to contact, and another 9% reported that it took them longer than usual but finally they were able to discuss their problem.

DISCUSSION

Spain has been hardly affected by the coronavirus pandemic . Despite the severe lockdown measures, there has been a high number of infected patients and an increased mortality of almost 47,000 people compared with the previous year . One big concern of the healthcare system, which was saturated with coronavirus‐infected patients, has been the management of other acute and chronic diseases . Specific guidelines for the different neurological diseases have been developed by national and international scientific societies . Nevertheless, many PWE have thought (and they still do) that their condition puts them at a significant risk for coronavirus (either being more likely to get infected or having a more severe disease) . Our survey showed that only a small minority of our population of patients had confirmed coronavirus infection (only 1.9%), with an additional 10% reporting some suggestive symptoms not confirmed by appropiate testing . Additionally, among those patients with seizures, more than 90% did not have them with fever, cough or fatigue, so they were likely to be unrelated to coronavirus infection. Seizure frequency or severity did not seem to increase in the majority of patients (56%) which differs to past SARS outbreaks in China . However, 31.2% of them reported having more or much more frequent seizures during lockdown. This was significantly higher in patients with sleep and mood disorders Anxiety and depressed mood, affecting 47% of our patients, and likely reactive to the difficult health and economic situation of the country , contributed to seizure frequency aggravation. Anyhow, few patients needed rescue medicines to abort seizures at home and few required assistance in the emergency room. Overall, the survey shows that patients were positively and negatively influenced by the lockdown. We have not had a shortage of ASM in Spain during the pandemic and most patients declared to take their medication regularly, likely because they had to stay at home and were able to focus on their health and be supervised by other family members. They also had fewer chances to be exposed to external triggers, such as alcohol overuse or sleep deprivation. Contrarily, lockdown brought about sleep and mood disorders in many patients, which seemed to be associated with seizure worsening. In our hospital and due to the emergency situation, no official telematic platform was implemented and all follow‐up visits were done by phone . In other countries like Italy, most patients who were scheduled for a follow‐up visit ended up not having them. Patients have also been able to reach for our nurse when needed . Physicians have been largely satisfied with this type of assistance, and we could find out that many patients (almost 70%) are open to the possibility of having this type of follow‐up (at least in some occasions) in the near future . We believe that continued care was determinant to help reducing patients fear and stresses the importance of maintaining a line of contact with chronic patients . Other european countries such as Italy , also severely impacted by SARS‐CoV‐2, emphasized the need for telemedicine assistance and pointed out similar results in their patients. They also observed increased seizure frequency in patients reporting sleep or mood disorders. However, a higher percentage of our patients had seizure deterioration, likely because our population includes more difficult to treat epilepsies. According to the results of their surveys in other centres across the world (for example USA , China and Iran ), patients experienced similar difficulties during the pandemic, with differences in the ability to obtain medications or to have access to their healthcare providers. The data provided by this informal survey set an exploratory frame from the perspective of PWE and may set the grounds for future interventions to ameliorate clinical assistance and be prepared for future challenges. The source of data is self‐reports which by definition are subjective and, compared with clinical sources, may yield inaccuracies . Symptoms such as behaviour or mood disorders could not be quantified by standardized tools; nevertheless, we believe the answers reflect the patients´ perspective and provide meaningful clinical information. In summary, our study shows a low rate of confirmed infection in PWE during coronavirus infection. The majority of patients had similar seizure frequency to their basal situation, although up to 30% have experienced more frequent seizures. Seizures have not occurred with fever and are likely more related to sleep or mood disorders that were reported by almost 50% of the respondents. Pandemic hitting hard on the public healthcare system has forced us to implement telematic visits for most patients with a positive embracement by most of the respondents.

CONFLICTS OF INTEREST

All authors declare no conflicts of interest related to this study. ߙ Click here for additional data file. ߙ Click here for additional data file.
  14 in total

1.  Validation of self-reported epilepsy for purposes of community surveillance.

Authors:  Daniel R Brooks; Ruzan Avetisyan; Kelli M Jarrett; Amresh Hanchate; G D Shapiro; M J Pugh; Dan R Berlowitz; David Thurman; Georgia Montouris; Lewis E Kazis
Journal:  Epilepsy Behav       Date:  2011-12-20       Impact factor: 2.937

2.  Keeping people with epilepsy safe during the COVID-19 pandemic.

Authors:  Jacqueline A French; Martin J Brodie; Roberto Caraballo; Orrin Devinsky; Ding Ding; Lara Jehi; Nathalie Jette; Andres Kanner; Avani C Modi; Charles R Newton; Archana A Patel; Page B Pennell; Emilio Perucca; Josemir W Sander; Ingrid E Scheffer; Gagandeep Singh; Emma Williams; Jo Wilmshurst; J Helen Cross
Journal:  Neurology       Date:  2020-04-23       Impact factor: 9.910

3.  Recommendation for an internationally agreed minimum data set for teleneurology.

Authors:  Kathleen L Bagot; Dominique A Cadilhac; Christopher F Bladin
Journal:  Nat Rev Neurol       Date:  2018-11       Impact factor: 42.937

4.  Severe psychological distress among patients with epilepsy during the COVID-19 outbreak in southwest China.

Authors:  Xiaoting Hao; Dong Zhou; Zhe Li; Guojun Zeng; Nanya Hao; Enzhi Li; Wenjing Li; Aiping Deng; Mintao Lin; Bo Yan
Journal:  Epilepsia       Date:  2020-05-22       Impact factor: 5.864

5.  Epilepsy Care in the Time of COVID-19 Pandemic in Italy: Risk Factors for Seizure Worsening.

Authors:  Giovanni Assenza; Jacopo Lanzone; Francesco Brigo; Antonietta Coppola; Giancarlo Di Gennaro; Vincenzo Di Lazzaro; Lorenzo Ricci; Andrea Romigi; Mario Tombini; Oriano Mecarelli
Journal:  Front Neurol       Date:  2020-07-03       Impact factor: 4.003

6.  Epilepsy self-management during a pandemic: Experiences of people with epilepsy.

Authors:  Wendy R Miller; Jane Von Gaudecker; Andrea Tanner; Janice M Buelow
Journal:  Epilepsy Behav       Date:  2020-06-25       Impact factor: 2.937

7.  Impacts of the COVID-19 pandemic on Iranian patients with epilepsy.

Authors:  Ali A Asadi-Pooya; Mohsen Farazdaghi; Mehdi Bazrafshan
Journal:  Acta Neurol Scand       Date:  2020-07-22       Impact factor: 3.915

8.  Emergency implementation of telemedicine for epilepsy in Spain: Results of a survey during SARS-CoV-2 pandemic.

Authors:  Estefanía Conde-Blanco; María Centeno; Ester Tio; Desiree Muriana; Juan José García-Peñas; Pedro Serrano; Antonio Gil Nagel; Jose Serratosa; Ángeles Pérez Jiménez; Manuel Toledo; Antonio Donaire; Isabel Manzanares; Olga Betrán; Mar Carreño
Journal:  Epilepsy Behav       Date:  2020-06-05       Impact factor: 2.937

9.  The resilience of the Spanish health system against the COVID-19 pandemic.

Authors:  Helena Legido-Quigley; José Tomás Mateos-García; Vanesa Regulez Campos; Montserrat Gea-Sánchez; Carles Muntaner; Martin McKee
Journal:  Lancet Public Health       Date:  2020-03-18

10.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.

Authors:  Zunyou Wu; Jennifer M McGoogan
Journal:  JAMA       Date:  2020-04-07       Impact factor: 56.272

View more
  7 in total

1.  Seizures and COVID-19: Results from the Spanish Society of Neurology's COVID-19 registry.

Authors:  Santiago Fernández Fernández; Javier Ricardo Pérez Sánchez; Guillermo Hernández Pérez; María Rabasa Pérez; Cristina Guijarro Castro; David García-Azorín; David Ezpeleta
Journal:  J Clin Neurosci       Date:  2022-05-16       Impact factor: 2.116

2.  Medium-term effects of COVID-19 pandemic on epilepsy: A follow-up study.

Authors:  Sofía Lallana; Elena Fonseca; Juan Luis Restrepo; Manuel Quintana; Iván Seijo-Raposo; Laura Abraira; Estevo Santamarina; José Álvarez-Sabín; Manuel Toledo
Journal:  Acta Neurol Scand       Date:  2021-04-27       Impact factor: 3.209

Review 3.  Patient Preferences for Subcutaneous versus Intravenous Administration of Treatment for Chronic Immune System Disorders: A Systematic Review.

Authors:  Paul M Overton; Natalie Shalet; Fabian Somers; Jeffrey A Allen
Journal:  Patient Prefer Adherence       Date:  2021-04-19       Impact factor: 2.711

4.  Impact of COVID-19 on the lives and psychosocial well-being of persons with epilepsy during the third trimester of the pandemic: Results from an international, online survey.

Authors:  Charissa Millevert; Stijn Van Hees; Joseph Nelson Siewe Fodjo; Veerle Wijtvliet; Edlaine Faria de Moura Villela; Barbara Rosso; Antonio Gil-Nagel; Sarah Weckhuysen; Robert Colebunders
Journal:  Epilepsy Behav       Date:  2021-01-29       Impact factor: 3.337

5.  [Valproic Acid Could Help in the Fight Against COVID-19: a case-control study].

Authors:  Oscar Moreno-Pérez; Esperanza Merino; Jose Manuel Ramos; Juan Carlos Rodríguez; Carmina Diaz; Patricio Mas; Sergio Reus; Rosario Sánchez-Martínez; Vicente Boix; Pablo Chico-Sánchez; José Sánchez-Payá; Joaquín Portilla
Journal:  Neurologia       Date:  2022-02-14       Impact factor: 3.109

6.  Seizure Control in Patients with Epilepsy during the COVID-19 Pandemic: A Systematic Review and Meta-analysis.

Authors:  Naoto Kuroda; Prasannakumar Kanubhai Gajera; Hongxuyang Yu; Takafumi Kubota
Journal:  Intern Med       Date:  2022-05-31       Impact factor: 1.282

7.  Long-term analysis of the effects of COVID-19 in people with epilepsy: Results from a multicenter on-line survey across the pandemic waves.

Authors:  Chiara Parodi; Ilaria Viganò; Emerenziana Ottaviano; Valentina Massa; Elisa Borghi; Simone Beretta; Jacopo C Di Francesco; Valeria Badioni; Aglaia Vignoli
Journal:  Epilepsy Behav       Date:  2022-08-25       Impact factor: 3.337

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.